Budipine in Parkinson's tremor

Journal of the Neurological Sciences

Volumn 248, Issue 1-2, 2006, Pages 53-55

  Reichmann, Heinz ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Budipine; NMDA receptor antagonist; Parkinson's disease; QT interval; Tremor

Indexed keywords

AMANTADINE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BUDIPINE; LEVODOPA;

ANOREXIA; ANXIETY; ARTICLE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; HALLUCINATION; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MONOTHERAPY; NAUSEA; PARKINSON DISEASE; PATIENT MONITORING; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; STEADY STATE; THERAPY EFFECT; TORSADE DES POINTES; TREMOR; XEROSTOMIA;

ANIMALS; ANTIPARKINSON AGENTS; HUMANS; PARKINSON DISEASE; PIPERIDINES; TREMOR;

EID: 33750466207     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.05.039     Document Type: Article

References (15)

1. Diener H.C. Leitlinien für Diagnostik und Therapie in der Neurologie (2003), Thieme, Stuttgart, New York
2. Reichmann H., Brecht M.H., Koster J., Kraus P.H., and Lemke M.R. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs 17 (2003) 965-973
3. Przuntek H., and Stasch J.P. Biochemical and pharmacologic aspects of the mechanism of action of budipine. In: Gerstenbrand F., Poewe W., and Stern G. (Eds). Clinical experiences with budipine in Parkinson therapy (1985), Springer, Berlin 107-112
4. Jackisch R., Huang H.Y., Reimann W., and Limberger N. Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissues in vitro. J Pharmacol Exp Ther 264 (1993) 889-898
5. Klockgether T., Jacobsen P., Löschmann P.A., and Turski L. The antiparkinsonian agent budipine is an N-methyl-d-aspartate antagonist. J Neural Transm Park Dis Dement Sect 5 (1993) 101-106
6. Kornhuber J., Herr B., Thome J., and Riederer P. The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. J Neural Transm Suppl 46 (1995) 131-137
7. Starr M.S. Antiparkinsonian actions of glutamate antagonists-alone and with l-DOPA: a review of evidence and suggestions for possible mechanisms. J Neural Transm Park Dis Dement Sect 10 (1995) 141-185
8. Parsons C.G., Quack G., Bresink I., Baran L., Przegalinski E., Kostowski W., et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34 (1995) 1239-1258
9. Przuntek H, Budipine Study Group. Budipine treatment in Parkinson's disease. Poster at the 4th International Congress on Progress in Alzheimer's and Parkinsonian Disease, Eilat/Israel (1997)
10. Jellinger K., and Bliesath H. Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo. J Neurol 234 (1987) 280-282
11. Malsch U., Bliesath H., Bother K., Ramm H., and Luhmann R. Monotherapy of Parkinson's disease with budipine. A double-blind comparison with amantadine. Fortschr Neurol Psychiatr 69 (2001) 86-89
12. Przuntek H., and Budipine Study Group. Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol 59 (2002) 803-806
13. Spieker S., Brfeit S., Klockgether T., and Dichgans J. Tremorlytic activity of budipine in Parkinson's disease. J Neural Transm Suppl 56 (1999) 165-172
14. Krüger H., Kohlhepp W., Reimann G., and Przuntek H. Prophylactic treatment of cluster headache with budipine. Headache 28 (1988) 344-346
15. Bien S., and Wörz R. Budipine treatment of neuroleptic-induced parkinsonism. In: Gerstenbrand F., Poewe W., and Stern G. (Eds). Clinical experience with budipine in Parkinson therapy (1985), Springer, Berlin 169-175